Spineway : First Mont-Blanc MIS implant in the USA

Posted On March 21, 2017 By OrthoSpineNews In Spine /

Ecully, 21 March 2017

Spineway, French specialist in surgical implants and instruments for treating disorders of the spinal column (spine), announces the completion of the first minimally invasive surgery using its Mont-Blanc MIS product line in the United States. The operation was performed by Dr. Ludwig Orozco, neurosurgeon in Dallas (Texas). It is a perfectly demonstrative achievement, given the patient condition was more complex than a typical lumbar osteoarthritis. A recent distribution agreement signed with SLR Medical Consulting was a driving force in this realization.

This first implantation of the Mont-Blanc MIS was performed on a patient presenting with degeneration on several vertebral levels. Its surgical treatment required the use of 8 pedicle screws and 2 titanium-alloy rods from Spineway’s innovative Mont Blanc MIS line. These instruments are perfectly adapted to meet practitioners’ growing needs for increasingly technological tools, like constructs involving over 3 vertebral levels, as in the present case. This line provides surgeons with highly technical instruments, all based on Spineway’s expertise in correcting spinal curvatures. The new Mont Blanc MIS instruments already allow for the treatment of several types of lumbar-spine disorders.

Minimally invasive surgery is currently the most dynamic segment of the worldwide market for spinal implants. Less traumatic for the patient, this type of surgery is less painful, and allows for a faster recovery and shorter hospital stays. This operating technique should, in the medium-term, become the standard technique for most surgeries.

This first successful operation allows Spineway to position itself in the US market on a high-growth segment with an innovative line offering surgeons a multitude of possibilities. Based on the success of its international launch, Spineway is continuing the commercial marketing and deployment of its already highly-technical products and plans to accelerate its R&D in order to widen the scope of application of its technologies, to cover a larger range of disorders.

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLAN FOR SMES)
Find out all about Spineway at www.spineway.com

Next communication:
2016 Annual Results – 25 April 2017, after market closes

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) – Talent INPI award (2015).
ISIN code: FR0011398874 – ALSPW

Contacts:


*Investor Relations* David Siegrist – Finance Director Tel: +33 (0)4 72 77 01 52 finance.dsg@spineway.com		*Financial Communication* Jérôme Gacoin / Solène Kennis Tel: +33 (0)1 75 77 54 68 skennis@aelium.fr

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/5e2e8d19-9523-4a51-896e-71446127fe6b

Spinal Elements® Announces Initial Procedures with Lucent® XP Expandable Interbody Implant

Posted On March 20, 2017 By OrthoSpineNews In Spine, Top Stories /

March 20, 2017

CARLSBAD, Calif.–(BUSINESS WIRE)–Spinal Elements, a spine technology company, announced that the first procedures with its Lucent XP expandable interbody implant have been successfully completed.

The Lucent XP System is an interbody device that can expand in height and increase in lordotic angle after it has been surgically implanted. The height expansion helps restore the height of the spinal disc space and the lordotic angling helps correct the curvature of the spine. With the Lucent XP device, surgeons can achieve up to 15 degrees of lordotic angle, helping restore sagittal balance for the patient.

The Lucent XP system is made primary of polyetheretherketone (PEEK), a radiolucent material with a lower modulus of elasticity than titanium, the primary material of many competitive systems. The PEEK mechanical properties along with the design of the device allow for a more load-sharing construct. The radiolucency allows for post-operative evaluation of the fusion progression. Additionally, the device is coated with Spinal Elements’ Ti-Bond® porous titanium coating. Ti-Bond is a hydrophilic coating applied at the bone-contacting endplates of the implant.

Hyun Bae, MD, a leading spine surgeon who practices at The Spine Institute in Los Angeles, California, had this to say about his experience with the Lucent XP System: “The ease of use of this system and the ability of the device to expand in height and restore lordotic angle are exactly what I need to address the challenges spinal fusion surgery for my patients.

Paul Kim, MD, of the Spine Institute of San Diego, added, “The clinical importance of height restoration and spinal curvature cannot be understated. Spinal Elements’ system provides these features without making sacrifices relative to construct rigidity or post-operative ability to monitor the progress of a fusion. Furthermore, I was able deploy the system safely and efficiently with a minimally invasive surgical approach.”

Spinal Elements will be more widely launching the Lucent XP expandable interbody device in the summer of 2017. The company has seen over 20% growth of the past year in its core technologies, fueled by demand for its advanced technologies including Ti-Bond coated implants.

About Spinal Elements

Spinal Elements, headquartered in Carlsbad, CA, is a spine technology company for spine surgeons who demand innovative, extremely high quality surgical solutions. From the company’s early work which helped make PEEK commonplace throughout the spine industry to recent advancements in Ti-Bond® porous titanium coated PEEK interbody implants and controlled delivery technology, Spinal Elements has built a reputation for being trustworthy, innovative and different. The company is focused on the development and marketing of progressive spinal treatment options and markets a complete portfolio of advanced spinal implant technologies. Additionally, the company distributes Hero® Allograft, the net proceeds from which are donated to charities benefiting children with life-threatening medical conditions. The company recently launched a warranty program for its Ti-Bond technology based on the success of over 10,000 devices implanted. For more information, please visit www.spinalelements.com.

Contacts

For Spinal Elements
Laura Charlton (formerly Johnson)
760.450.7749
laurajohnsonpr@yahoo.com

NuVasive announces new evidence-based recommendation released from NICE (U.K.) for Lateral Interbody Fusion

Posted On March 20, 2017 By OrthoSpineNews In Spine /

SAN DIEGO, March 20, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced updated guidance from the National Industry for Clinical Excellence (NICE) in the U.K. for lateral interbody fusion in the lumbar spine. NICE stated the evidence on efficacy for lateral interbody fusion is adequate in quality and quantity and the procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. The majority of the evidence submitted to and reviewed by the panel was peer-reviewed journal articles describing the now 14-year experience with and outcomes following the Company’s eXtreme Lateral Interbody Fusion (XLIF®) procedure, the leading global lateral approach spine surgical technique.

“Our continued investment into clinical research and outcomes data from our XLIF procedure was supportive in NICE releasing updated guidance for this innovative surgical approach,” said Jason Hannon, NuVasive’s president and chief operating officer. “Our team has worked diligently with NICE since 2015 to gather, analyze and review the available evidence. The updated guidance further supports the clinical efficacy of XLIF and will help expand the availability of XLIF to back pain sufferers in the U.K. and around the world.”

With more than 150,000 successful surgeries around the world, XLIF is the leading global lateral approach procedure. First introduced in the U.S. in 2003, XLIF is a minimally invasive surgical procedure performed through the side of the body, utilizing proprietary neuromonitoring and an integrated portfolio of instruments and specialized implants for treating a range of spinal pathologies.

Initial NICE guidance for lateral interbody fusion was published in 2009 with additional special measures that impacted adoption of the procedure in the UK. In response to a request for input prior to a planned re-review of NICE guidance, NuVasive submitted a large body of evidence for the XLIF procedure, including data outlining safety profile, rate of fusion, and improvements in pain and disability. The updated guidance was supported by a systematic literature review of more than 200 previously published studies as a high-quality summary of the safety and efficacy of the XLIF procedure¹. For more information on the updated NICE guidance for lateral interbody fusion, visit https://www.nice.org.uk/guidance/ipg574.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $956 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

¹ Lehmen JA et al. Eur Spine J 2015;24(Suppl 3):S287–S313

CONTACT: Investor Contact: Suzanne Hatcher, NuVasive, Inc., 858-458-2240, investorrelations@nuvasive.com; or Media Contact: Stefanie Mazer, NuVasive, Inc., 858-320-5243, media@nuvasive.com

Mazor Robotics and Medtronic Combine Efforts on the Commercialization of Mazor X™: An Innovative Guidance System for Spine Surgery

Posted On March 20, 2017 By OrthoSpineNews In Robotics, Spine /

ORLANDO, Fla., March 17, 2017 /PRNewswire/ — Mazor Robotics Ltd. is a global leader in the development and distribution of innovative surgical guidance systems for spine and brain surgery. Mazor Robotics Inc., the US subsidiary of Mazor Robotics LTD is recognized as one of largest players in the robotics and simulation industry in the State of Florida, their US headquarters are in downtown Orlando. In nearby Celebration, The Florida Hospital Nicholson Center serves as the national training center for the new Mazor X™, a transformative platform for spine surgeries, having trained over 100 surgeons from all over the United States in 2016.

“As a pioneer and a leader in the field of surgical guidance systems, Mazor Robotics saw two significant milestones in 2016: the launch of our strategic partnership with Medtronic followed by the commercial release of the new Mazor X™. We are very excited to see what 2017 brings for our company,” says: Christopher Prentice, CEO Mazor Robotics, Inc.

Since signing the agreement in May 2016, Mazor and Medtronic have invested in co-marketing, promotion, and training efforts towards commercialization of Mazor X™, a transformative platform for spine procedures that launched in October at the North American Spine Society (NASS) Annual Meeting. Between the two companies, there are now hundreds of highly experienced capital and clinical specialists responsible for raising the awareness of, selling and supporting Mazor X.

Mazor Robotics (TASE: MZOR; NASDAQ-GM: MZOR) believes in healing through innovation by developing and introducing revolutionary technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

SOURCE Mazor Robotics Ltd.

Degree of spinal deformity affects hip replacement surgery success

Posted On March 20, 2017 By OrthoSpineNews In Recon, Spine /

PUBLIC RELEASE: 17-MAR-2017 – NYU LANGONE MEDICAL CENTER / NEW YORK UNIVERSITY SCHOOL OF MEDICINE

People with spinal deformity also requiring a total hip replacement are at greater risk for dislocation or follow-up revision surgery, suggesting that these higher-risk patients may benefit from a more personalized approach to their surgeries to reduce the risk of poorer outcomes.

A new study led by orthopaedic surgeons at NYU Langone Medical Center provides a greater understanding of exactly how spinal deformity interacts with the pelvis, potentially increasing risk despite implanting the artificial hip in what is traditionally considered a “safe zone” by surgeons.

“Surgeons should anticipate potential instability after performing a hip replacement in patients who have existing spinal deformity, and they should adjust their surgical plans accordingly,” says lead study author Aaron J. Buckland, MD, assistant professor of Orthopaedic Surgery in the division of Spine Surgery and director of spine research at NYU Langone.

The study was presented March 17, 2017 at the American Academy of Orthopaedic Surgeons (AAOS) 2017 Annual Meeting in San Diego, California. These findings also were published online December 27, 2016 in the Journal of Arthroplasty.

More than 310,000 hip replacements are performed in the U.S. each year, with rates dramatically increasing over the past two decades in younger adults 45 to 64 years of age who are active and living longer than ever before. An estimated 2.5 million Americans are currently living with hip replacements.

In a hip replacement, an artificial joint comprised of a ball and socket is implanted to replace the natural socket in the pelvis, enabling movement that is typical of the hip joint. For the past 40 years, surgeons have placed the socket (known as the acetabular cup) adjacent to the pelvic bone in a so-called “safe zone” — a position that is thought to reduce risk of dislocation. However, the new research suggests that placing the cup in the safe zone may not be enough to prevent dislocation in patients with spinal deformity.

Until now, no studies of the hip-spine relationship have focused on patients with sagittal spinal deformity, says Dr. Buckland. “Our research helps bridge any disconnect between surgeons who regularly treat spinal deformities and those who perform hip joint replacements, fostering more collaboration to improve patient outcomes,” he adds.

READ THE REST HERE

AAEAAQAAAAAAAAifAAAAJDkxMGJkMGQwLTI3MTktNDA3NS1iM2Y5LTdjZjhjYTVhYjRiNw.jpg

Leading International Spine Surgeons Praise AxioMed Viscoelastic Disc as “Game Changer” for Spine Surgery

Posted On March 20, 2017 By OrthoSpineNews In Spine /

MALDEN, MA (PRWEB) MARCH 15, 2017

Leading internationally renowned surgeons and their patients have hope that AxioMed’s first-of-its-kind viscoelastic disc replacement – which acts as a cushion between the vertebrae – will give hope to millions who suffer from back and neck pain and who are looking to maintain their normal activities post spine surgery.

Surgeons and patients who have experience with the AxioMed Freedom Disc have reacted overwhelmingly positively. “I have seen some of the postoperative X-rays noting that the AxioMed disc restores height, restores normal motion, and more patients are giving testimonials on getting back their quality of life,” says AxioMed President Jake Lubinski.

Dr. Kenneth Pettine, an experienced total disc replacement spine surgeon and part of the lumbar IDE study, calls it “the best artificial lumbar disc there is.” Dr. Robert Pflugmacher, spinal surgeon from Bonn, Germany, credits ease of use and positive results to AxioMed’s success in spinal disc rankings. The disc “imitates our nature, because our natural disc is viscoelastic,” explains Professor Dr. Burkhard Rischke.

Patient testimonials are life changing. Patient Kristen Lee, personal trainer and yoga instructor, explains, “I find that having undergone the Freedom Total Disc Replacement surgery, I have been given back my life. I was able to walk the next day without pain. I am more active now than I was pre-surgery.” Marathon runner and TDR patient Robert Ramsey credits the AxioMed disc immensely, stating, “The Freedom Disc has given me my life back.” Former American Gladiator winner Robin Coleman is back to her lifestyle and enjoying riding horses again.

Dr. Kingsley R. Chin points out the mechanics of the disc’s success, outlining, “When you look at this disc with its viscoelastic properties you now have a disc that truly mimics the human disc. The bond between the viscoelastic material and the Titanium endplates are very strong and its a single piece device no moving pieces. And so now, you are able to insert this disc easily. It’s going to be reliable for longevity. It’s a one piece device that does not have a keel. So putting this disc anteriorly in the lumbar spine or cervical spine is pretty easy. The ability for us to then put it in laterally in the lumbar spine, I think will be a game changer, and that’s what we’re going to do.”

View full video coverage here.

Medacta International Expands Relationship With OREF to Advance Orthopedic Research and Innovation

Posted On March 16, 2017 By OrthoSpineNews In Financial, Recon, Spine /

March 16, 2017

CHICAGO–(BUSINESS WIRE)–Medacta International, the privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, today reaffirmed its partnership with the Orthopaedic Research and Education Foundation (OREF) to advance new frontiers of orthopedic discovery. Effective immediately, and building upon their work together over the past two years, Medacta has increased its support and will now match resident gifts two-to-one, up from its original commitment of one-to-one. Importantly, this program encourages residents to engage in charitable giving at an early state in their careers and prioritizes OREF as a beneficiary of their philanthropy.

Since the program started in 2015, the Medacta Challenge raised more than $150,000 for OREF. This includes contributions to OREF’s Research Fund from Francesco Siccardi, Executive Vice President of Medacta International, and Eric Dremel, President of Medacta USA, who each pledged $20,000 to kick off the partnership and demonstrate their commitment to the initiative. Mr. Siccardi and Mr. Dremel were recognized for their gifts as members of OREF’s Visionary Research Society.

“We believe the next big innovation is always just around the corner and are excited that our expanded partnership with OREF will make already generous resident contributions even more impactful,” said Siccardi. “This partnership drives Medacta and OREF’s shared goal of providing the best possible care to improve the lives of patients around the globe.”

All gifts made to OREF through the Medacta Challenge help OREF achieve its mission of funding new and seasoned investigators in the orthopedic field. This funding may be used to support research in orthopedic trauma, total joint arthroplasty, soft tissue repair and regeneration, among other important topics. With Medacta’s increased commitment, the impact of resident donations will be tripled to provide investigators with necessary resources to conduct these important studies.

“OREF relies on the generosity of organizations like Medacta to continue supporting research in orthopaedics,” said David Lewallen, MD, OREF Board President. “The grants we provide enable innovators to push the envelope and be bold, effectively creating change in the orthopaedic discipline – ultimately providing patients with safer, better options, and a higher quality of life. None of this would be possible without our committed partners such as Medacta.”

Richard Santore, MD, Trustee and Chair of OREF’s Individual Development Committee, added, “We are particularly excited that Medacta’s matching gift program will not only support our investigators, but will encourage other individuals and companies to consider establishing additional creative concepts for making gifts to OREF. Working together to promote new studies and drive creative solutions will benefit us all and, most importantly, the patients we serve together. Medacta is to be commended for their leadership and generosity for this multi-year commitment to OREF.”

Since Medacta’s founding in 1999, the company has maintained a long tradition of prioritizing research and training, the foundations of orthopedics. Through training initiatives, such as the company’s M.O.R.E. Institute, Medacta promotes surgeon education and provides the tools for physicians to refine their skills. The company has trained over 5,000 surgeons at its learning centers, while its biennial M.O.R.E. International Symposium consistently attracts hundreds of renowned surgeons from across the world.

For more information about Medacta, please visit medacta.com or follow @Medacta on Twitter.

About Medacta

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

About the Orthopaedic Research and Education Foundation

Founded in 1955, the Orthopaedic Research and Education Foundation is a charitable 501(c)(3) organization committed to improving lives by supporting excellence in orthopaedic research. OREF is dedicated to supporting new investigators and is the premiere orthopaedic organization funding research across all specialties. A list of research and funding priorities is available at oref.org/grants. To learn more about OREF, please visit www.oref.org or follow @OREFtoday on Twitter.

Contacts

For Medacta International, Inc.
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com
or
For OREF
Karen Pubentz, 847-430-5113
pubentz@oref.org

Zimmer Biomet Showcases New Product Innovation, Novel Digital Health Offering and Robotic Technology at AAOS 2017

Posted On March 15, 2017 By OrthoSpineNews In Extremities, Robotics, Spine /

WARSAW, Ind., March 14, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced plans to highlight its latest commercial offerings and preview its next generation of technological innovations at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting this week in San Diego, CA. The Company’s state-of-the-art booth (#4333) will feature an immersive and interactive tour of its newly launched digital technology and clinical services offering, Zimmer Biomet Signature Solutions, alongside more than 50 new products from its vast and diversified portfolio.

“We’re proud and excited to showcase our most innovative new commercial offerings to the largest gathering of orthopaedic professionals,” said David Dvorak, President and CEO of Zimmer Biomet. “New this year is a virtual booth experience designed to bring Zimmer Biomet Signature Solutions to life through a guided tour, a sneak preview of our emerging robotics platform and other technologies in our deep pipeline.”

Following is a snapshot of the key highlights being featured at the Zimmer Biomet booth (#4333) at AAOS 2017:

Zimmer Biomet Signature Solutions
- Guided tours through the virtual experience every 15 minutes. Members of the press can reserve a spot by contacting Monica Kendrick at monica.kendrick@zimmerbiomet.com.
Robotic Technology
- Catch a glimpse of the future of personalization and intelligent instrument technology through innovative robotics.ⁱ
Knees
- Vanguard^® Individualized Design (ID), advances soft tissue preservation and balancing through independent medial and lateral articular surface constraint and thickness options.
- OSS^TM Orthopedic Salvage System, a comprehensive modular platform providing surgeons with intraoperative flexibility often required during limb salvage procedures.
- Persona^® Medial Congruent^® Bearing, designed to recreate more natural feeling motion of the human knee by maximizing knee joint stability while allowing mobility.
Hips
- Hip Preservation portfolio of options designed to treat conditions leading up to osteoarthritis and potentially preventing the need for total hip replacement.
- Trabecular Metal^TM acetabular cups, which National Joint Registry analysis has recently shown are 21 percent less likely to be re-revised due to infection (statistically significant, p-value=0.036).ⁱⁱ
- The latest in dual mobility, Microplasty^® and revision implant options designed to address the distinct needs of individual patients while simplifying surgical workflow.
Personalized Solutions
- A comprehensive technology-based portfolio of guides, tools and software to support surgical planning, intraoperative guidance and optimal component placement.
Bone Cement
- StageOne^TM and StageOne Select Spacer Molds, designed to mold a temporary knee, hip and shoulder spacer for patients undergoing a two stage revision due to an infected total joint.
Diagnostics
- Synovasure^® Laboratory Panel for the detection of Periprosthetic Joint Infection (PJI), now includes Microbial ID. These diagnostic tests provide a fast and easy method to diagnose PJI based on the flagship test, which determines the concentration of Alpha Defensin in synovial fluid. Microbial ID detects the presence of microbes in the synovial fluid in a matter of hours.
Extremities
- Vault Reconstruction System (VRS), the first commercially available patient-matched glenoid implant, cleared to specifically treat patients with severe glenoid bone loss and a deficient rotator cuff.
- L2L^TM Radial Head System, a simple, smooth design solution for replacing the proximal radial head in patients with fractures.
Foot and Ankle
- Deformity correcting products available through our partnership with Nextremity Solutions, Inc., including the Nextra^®Hammertoe Correction System, the MSP™ Metatarsal Shortening System and the Re+Line^® Bunion Correction System.
- Subchondroplasty^® Procedure for foot and ankle surgery, a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions.
Trauma
- A.L.P.S.^® Proximal Humerus Plating System, designed to minimize the risk of complications commonly associated with proximal humerus fractures, such as varus collapse, articular screw penetration and subacromial impingement.
- N-Force Fixation System^® with N-Force Blue, an augmented fixation system, integrating fenestrated screws and a Bone Substitute Material into a single construct to provide improved metaphyseal void fill and increase structural support of the implant.
- RibFix Blu^® Thoracic Fixation System, designed and used for the stabilization and rigid fixation of fractures in the chest wall, including sternal reconstructive surgical procedures, trauma or planned osteotomies.
Sports Medicine
- Quattro^® Link, a knotless anchor that brings control and efficiency to soft tissue repair.
- BioWick^TM SureLock^®, a rotator cuff implant that is an interpositional bioresorbable scaffold wick.
- SpeedSnare^TM Surgical Suture Passer, which allows the ability to pass a suture through single or multiple ports.
- Gel-One^® Cross-Linked Hyaluronate, the first low-volume viscosupplement available in a single-injection formula, for the treatment of pain in osteoarthritis of the knee that does not respond adequately to other conservative treatments.
Biologics
- nSTRIDE^® Autologous Protein Solution (ex-US use only), a single-shot autologous anti-inflammatory for treatment of knee osteoarthritis.
- AmnioFlo^TM, allograft derived from human amniotic fluid, for joint cushioning and lubrication.
Surgical
- The IntelliCart™ System Duo Fluid Carts, the foundation for infectious waste technology with market-leading 34-liter capacity, extra quiet vacuum pump, clog-free suction manifolds and portable smoke evacuation.
- Bactisure™ Wound Lavage, clear, low-odor, aqueous solution designed to remove structurally resistant forms of bacteria, including biofilms, on all wound types.
- The VasoPress^® System, reduces the risk of blood clots associated with deep vein thrombosis by propelling the venous blood out of the deep veins while patients are undergoing surgical procedures or immobile for an extended period of time.
Spine
- Mobi-C^® Cervical Disc, the first cervical disc replacement device approved for both one and two-level procedures.
- Vitality^® Spinal Fixation System, an adaptable system designed for spinal fixation in complex thoracolumbar procedures.

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

ⁱ Concept device – not for sale in the US

ⁱⁱ 1. According to NJR data from 2003 to 2015 where 9,573 Trabecular Metal and 30,452 non-Trabecular Metal cups were used in revision THA and based on hazard ratios adjusted by patient gender, age group, and indications (OA/non-OA).

2. NJR data shows a higher percentage of TM cups were used with antibiotic bone cement compared to all other non-TM cementless cups.

SOURCE Zimmer Biomet Holdings, Inc.

Gary Henley Joins Spinal Simplicity, LLC as an Advisor and to Serve on the Board of Managers

Posted On March 15, 2017 By OrthoSpineNews In Spine /

OVERLAND PARK, KANSAS (PRWEB) MARCH 14, 2017

Spinal Simplicity, a medical device company developing innovative solutions to treat complex spinal and orthopedic surgical problems, announces Gary Henley has agreed to serve as an Advisor and will join the Company’s Board of Managers.

Gary Henley is an accomplished medical device executive with over 34 years of experience in the orthopedic industry. Most recently, Mr. Henley served as President, Chief Executive Officer and Board Member of United Orthopedic Group from 2011 to 2014. Prior to United Orthopedic Group, Mr. Henley served as President and Chief Executive Officer of Wright Medical Group, Inc. from 2006 to 2011. Mr. Henley also spent nine years at Orthofix International N.V. as President of its Americas Division from 1997 through 2006. Early in his career, Mr. Henley successfully created Cecorp, Inc., a surgical visualization pioneer in the arthroscopic and endoscopic markets and then sold the company to Smith & Nephew. After the sale in 1987, Mr. Henley served as President of Smith & Nephew’s Endoscopy Video Division until 1996. Mr. Henley has significant board experience, including Board Chairman of OrthoAlign, with similar roles at Orchid Orthopedic Solutions, Hutchinson Technology, Wright Medical Group, Innovative Spinal Technologies, and BioFuse Medical.

Todd Moseley, CEO of Spinal Simplicity said, “Gary’s decision to join Spinal Simplicity [as an Advisor and Member of our Board of Managers] reinforces our position that our innovative technology in the orthopedic and spine markets will bring about sweeping enhancements to the treatment options available to patients. Gary has successfully orchestrated transactions and built critical mass within companies that have dominated the spinal and orthopedic markets. Spinal Simplicity will benefit greatly from the industry expertise and healthcare-related innovations that have been the hallmark of Gary’s career. The fact that we can tap into Gary’s experience as we bring the Minuteman® G3-R to the minimally-invasive spine market will truly change the landscape of posterior supplemental fusion and fixation. Equally critical is the fact that Gary’s expertise in the extremities space will be invaluable to the company during development of the Wolff’s LawTM plating technology.”

Mr. Henley added, “I am excited about joining Spinal Simplicity’s Board. I think they have some very compelling technology in their products that will bring better clinical outcomes for patients, while also reducing the cost of doing certain procedures. It is going to be fun being part of the team that is bringing these innovative products to market.”

Spinal Simplicity’s Minuteman® family of sterile packed, posterior, non-pedicle supplemental fusion and fixation devices for use in the non-cervical spine (T1-S1) provide an alternative to traditional fixation, such as pedicle screws. The Minuteman® family of devices consists of a plating system intended for supplemental fusion in patients with degenerative disc disease, spondylolisthesis, trauma and tumor.

Spinal Simplicity will be exhibiting at the 2017 American Academy of Orthopaedic Surgeons meeting in San Diego, booth 659.

About Spinal Simplicity
Spinal Simplicity, LLC, headquartered in Overland Park, KS, is dedicated to the creation of simple solutions for the treatment of complex spinal and orthopedic problems. Spinal Simplicity has regulatory clearance for the Minuteman® system in the US, Europe and Canada. Our vision is to be the global leader in innovative, simplified surgical solutions, while delivering uncompromising quality. For more information, please visit http://www.spinalsimplicity.com

$Despite the known role of vitamin D in preventing osteoporosis, less than half of elderly hip fracture patients take supplements$

Despite the known role of vitamin D in preventing osteoporosis, less than half of elderly hip fracture patients take supplements

Posted On March 14, 2017 By OrthoSpineNews In Extremities, Spine /

SAN DIEGO, Calif., March 14, 2017 /PRNewswire-USNewswire/ — Despite national recommendations for daily vitamin D intake, a new study presented today at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that just 45.7 percent of patients reported consistently taking vitamin D supplements following a hip fracture, a known treatment and preventative strategy for osteoporosis.

In the U.S., an estimated 44 million people have osteoporosis and another 10 million are at risk for the disease which causes progressive bone loss and increased fracture risk. One in two women and one in four men older than age 50 years will sustain a bone fracture caused by osteoporosis. These potentially debilitating injuries include fractures of the hip, spine, wrist, arm or leg, often occurring from a fall. A bone fracture is often the first sign of the disease which develops slowly with no other symptoms. Treatments, which include medication, weight-bearing exercise, and/or vitamin D, calcium or estrogen supplements, can prevent subsequent fractures.

The U.S. Food and Nutrition Board (FNB) at the Institute of Medicine of The National Academies recommends 600 International Units (IUs) of vitamin D each day for adults, and 800 IUs for Americans age 71 and older.

In this study, Canadian researchers interviewed 573 hip fracture patients about their vitamin D intake during doctor visits for two years following hip fracture surgery. The mean patient age was 74.1, and the majority of patients (66.3 percent) were women.

Less than 50 percent (47.5 percent) of the patients consistently took vitamin D supplements as recommended, 35.6 percent took supplements inconsistently, and less than 19 percent took no supplements. Despite well-developed guidelines and close follow-up in a clinical trial, a low proportion of elderly hip fracture patients are consistently taking vitamin D. This suggests a need to develop and evaluate additional strategies to promote compliance.

“Vitamin D supplementation following hip fracture surgery is grossly under-prescribed,” said co-study author Mohit Bhandari, MD, an orthopaedic surgeon and research chair in musculoskeletal trauma and surgical outcomes, at McMaster University in Ontario, Canada. “Given its potential to improve patient function independent of other therapies, it seems improved advocacy and education—aimed at doctors and patients—about vitamin D supplementation is both worthwhile and evidence-based.”

Added co-study author Earl Bogoch, MD, an orthopaedic surgeon at the University of Toronto: “The benefits, safety and ease of taking vitamin D appear to be unknown or ignored by this representative cohort group of elderly osteoporotic patients who are identified by numerous guidelines as being most likely to benefit.”

The AAOS position statement, “Orthopaedic Care of Patients with Fragility Fractures,” recommends that U.S. physicians proactively screen, monitor, and, if necessary, assist in getting treatment for elderly and other at-risk patients for osteoporosis following an initial bone fracture to prevent subsequent fractures.

Study abstract

2017 AAOS Annual Meeting Disclosure Statements

The American Academy of Orthopaedic Surgeons
With more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world’s largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.

Visit AAOS at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.com/AAOS1
Twitter.com/AAOS1

This information is being sent to you by:
American Academy of Orthopaedic Surgeons
9400 W. Higgins Road, Rosemont, IL , 60018,
http://www.aaos.org

Spine

Contacts

Related Links

Contacts